Key clinical point: For patients with triple-negative breast cancer, neoadjuvant nab-paclitaxel may be more effective when given on a weekly basis than on a “two out of three” schedule.

Major finding: Among patients with triple-negative breast cancer who were treated with weekly nab-paclitaxel, 60.4% achieved pathologic complete response, compared with 50.0% who were treated with nab-paclitaxel on days 1 and 8 every 3 weeks (P = .056 with a prespecified significance threshold of alpha = .1).

Study details: The phase 3 GeparX study involved 780 patients with early-stage primary breast cancer.

Disclosures: The study was funded by Amgen and Celgene. The investigators reported additional relationships with AstraZeneca, Pfizer, Pharma Mar, Daiichi Sankyo, and others.